Germany First EU Country to Launch Wegovy Oral GLP-1
6 Articles
6 Articles
The largest EU countries are changing their philosophy of approaching obesity: it should no longer be seen as a lifestyle, but as a chronic disease.
Novo Nordisk’s oral obesity treatment, Wegovy pill, surpassed 5 million cumulative prescriptions in the United States just six months after its launch. Having entered the market before competitor Eli Lilly’s oral obesity treatment, Foundayo, Wegovy pill outpaced the speed of initial prescription expansion, intensifying competition among GLP-1 obesity treatments.
Novo Nordisk will also bring his tablet to the German market on September 1st against severe overweight. Top manager Emil Larsen explains how he wants to score against Eli Lilly.
I’ve taken the new Wegovy ‘skinny’ pill for a month. It finally broke my weight-loss plateau, writes LOUISE ATKINSON, but at what cost? Week by week, here’s my honest account of EVERYTHING that happened…
When a box containing my first pack of Wegovy pills arrived I was excited – until, that is, I spotted the stash of extra medication to help with side-effects tucked in beside them. After 18 months of weekly Mounjaro jabs I was looking forward to swapping all the druggy paraphernalia (refrigerated syringe pen, spare needles, alcohol wipes, sharps bin) for the simplicity of swallowing a tiny tablet once a day. I’d put my name on a waiting list and…
Novo Nordisk weight-loss pill hits Germany in Sept - The Copenhagen Post
According to news agency Reuters, Novo Nordisk will launch its weight loss drug Wegovy in pill form in Germany in September, making Germany its first market in the EU. The US was the first market to launch the pill earlier this year, followed by the United Arab Emirates and the UK. Following its second-quarter report, […]
Coverage Details
Bias Distribution
- 67% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
